Subject has indeterminate, ulcerative, antibiotic-associated colitis. 
Subject has stool positive for ova and parasite and for Clostridium difficule toxins within 3 months prior to enrollment. 
Subject with other known infectious cause of abdominal symptoms. 
Subject with clinical evidence of renal disease with the past 6 months, defined as estimated glomerular filtration rate (GFR) outside the normal reference range. 
Subject with known history of intestinal obstruction or current obstructive symptoms, such as severe abdominal pain with accompanying nausea or vomiting, based on investigator judgment. 
Subject with a diagnosis of gastroparesis or small bowel or large bowel dysmotility. 
Subjects with a history of small bowel or colonic resection. 
Subject with any current condition believed to have an increased risk of capsule retention such as suspected or known bowel obstruction, stricture, or fistula. 
Subject has used non-steroidal anti-inflammatory drugs including aspirin, two times per week, during the 4 weeks preceding enrollment. Low dose aspirin regimens (< 100 mg daily) are acceptable and not exclusionary. 
Subject suffers from any condition, such as swallowing problems, that precludes compliance with study and/or device instructions. 
Subject with cardiac pacemaker or other implanted electromedical device. 
Subject has an allergy or other known contraindication to the medications used in the study. 
Subject is pregnant (documented by a positive pregnancy test) or is actively breast-feeding. 
Subject is considered to be a part of a vulnerable population (eg. prisoners or those without sufficient mental capacity). 
Subject has a known contraindication to MRE or IC. 
Subject has participated in a drug or device research study within 30 days of enrollment that may interfere with the subject's safety or ability to participate in the study. 
Subject has any medical condition that would make it unsafe for them to participate, per Investigator's descretion       
    

NCT03241368_exc_T1
Condition
colitis
NCT03241368_exc_T2
Observation
antibiotic-associated
NCT03241368_exc_T3
Observation
ulcerative
NCT03241368_exc_T4
Observation
indeterminate
NCT03241368_exc_T5
Measurement
stool
NCT03241368_exc_T6
Value
positive for ova
NCT03241368_exc_T7
Value
parasite positive for
NCT03241368_exc_T8
Value
Clostridium difficule toxins positive for
NCT03241368_exc_T9
Temporal
within 3 months prior
NCT03241368_exc_T10
Reference_point
enrollment
NCT03241368_exc_T12
Condition
renal disease
NCT03241368_exc_T13
Temporal
with the past 6 months
NCT03241368_exc_T14
Measurement
estimated glomerular filtration rate (GFR)
NCT03241368_exc_T15
Value
outside
NCT03241368_exc_T16
Reference_point
normal reference range
NCT03241368_exc_T17
Condition
intestinal obstruction
NCT03241368_exc_T18
Observation
history
NCT03241368_exc_T19
Condition
obstructive symptoms
NCT03241368_exc_T20
Temporal
current
NCT03241368_exc_T21
Condition
severe abdominal pain
NCT03241368_exc_T22
Condition
nausea
NCT03241368_exc_T23
Condition
vomiting
NCT03241368_exc_T24
Condition
gastroparesis
NCT03241368_exc_T25
Condition
small bowel
NCT03241368_exc_T26
Condition
large bowel dysmotility
NCT03241368_exc_T27
Condition
small bowel resection
NCT03241368_exc_T28
Condition
colonic resection
NCT03241368_exc_T29
Observation
history
NCT03241368_exc_T31
Drug
non-steroidal anti-inflammatory drugs
NCT03241368_exc_T32
Drug
aspirin
NCT03241368_exc_T33
Multiplier
two times per week
NCT03241368_exc_T34
Temporal
during the 4 weeks preceding
NCT03241368_exc_T35
Reference_point
enrollment
NCT03241368_exc_T36
Drug
aspirin
NCT03241368_exc_T37
Multiplier
< 100 mg daily
NCT03241368_exc_T38
Qualifier
Low dose
NCT03241368_exc_T40
Condition
condition
NCT03241368_exc_T41
Condition
swallowing problems
NCT03241368_exc_T42
Negation
precludes
NCT03241368_exc_T45
Scope
compliance with study and/or device instructions
NCT03241368_exc_T46
Scope
condition, such as swallowing problems
NCT03241368_exc_T47
Device
cardiac pacemaker
NCT03241368_exc_T48
Device
implanted electromedical device
NCT03241368_exc_T49
Condition
allergy
NCT03241368_exc_T50
Condition
contraindication
NCT03241368_exc_T51
Drug
medications used in the study
NCT03241368_exc_T52
Scope
allergy or other known contraindication
NCT03241368_exc_T53
Condition
pregnant
NCT03241368_exc_T54
Value
positive
NCT03241368_exc_T55
Measurement
pregnancy test
NCT03241368_exc_T56
Qualifier
actively
NCT03241368_exc_T57
Temporal
actively
NCT03241368_exc_T58
Observation
breast-feeding
NCT03241368_exc_T59
Person
part of a vulnerable population
NCT03241368_exc_T60
Person
prisoners
NCT03241368_exc_T61
Condition
without sufficient mental capacity
NCT03241368_exc_T62
Scope
prisoners or those without sufficient mental capacity
NCT03241368_exc_T63
Condition
contraindication
NCT03241368_exc_T64
Procedure
MRE
NCT03241368_exc_T65
Procedure
IC
NCT03241368_exc_T66
Scope
MRE or IC